Core Viewpoint - The first domestically developed GLP-1 weight loss innovative drug, Masitide Injection, is expected to be approved soon, potentially disrupting the current market dominated by multinational giants Novo Nordisk and Eli Lilly [1] Group 1: Drug Approval and Market Impact - Masitide is the world's first GCG/GLP-1 dual receptor agonist for weight loss, which could enhance the accessibility of GLP-1 weight loss medications [1] - The drug is anticipated to receive approval as early as this week, marking a significant milestone in the weight loss pharmaceutical sector [1] Group 2: Market Activity and Pricing - Despite the drug not yet being approved, private hospitals have begun accepting reservations for Masitide Injection through online platforms [1] - A private clinic in Shanghai is offering a group purchase coupon for an initial dosage of 2mg (2 vials) at a reservation price of 500 yuan [1]